About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.
UgenTec's FastFinder software platform uses artificial intelligence to enable analysis and interpretation of qPCR data, workflow automation, and genotyping.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
